

Pathway for management of high risk stable coronary disease patients as per NICE TA607 - Rivaroxaban (XARELTO®) for preventing atherothrombotic events in people with coronary or peripheral artery disease

The pathway below has been adapted from a document produced by NNUH Cardiology Consultants for the Cardiology Clinical Governance Meeting in November 2020. It identifies patients with stable coronary disease who may be at high risk of further complications. This may make them eligible for treatment with twice daily Rivaroxaban 2.5mg as per 'TA607 - Rivaroxaban (XARELTO®) for preventing atherothrombotic events in people with coronary or peripheral artery disease'. (Recommendations were approved by TAG and D+TC in January 2021. Ratified by CCG Chair – March 2021.)

